GSK recruiting 150 for Costa Rica ops center; Takeda plans $2.7B charge for Actos settlement;

@FiercePharma: $GSK buoyed by early numbers on Anoro, Breo DTC campaigns. More | Follow @FiercePharma

@EricPFierce: Manufacturing plant cost baked into $2.5B Biogen CEO says it will cost to develop Alzheimer's drug. Item | Follow @EricPFierce

@CarlyHFierce: What's in a (drug) name? We asked the #FierceMadness champs. Article | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) said it would hire 150 new workers in Costa Rica to expand its business services operations there. Report

> Takeda Pharmaceutical will take a $2.7 billion charge against fiscal 2014 earnings to cover its $2.4 billion agreement to settle liability cases over its diabetes drug Actos. Report

> Ariad Pharmaceuticals ($ARIA) CEO Harvey Berger will retire as part of a deal with activist investor Sarissa Capital Management. Report

> France's Ipsen said sales rose to 350 million euros in the first quarter, up from 305.9 million euros a year ago, with specialty drug sales up 10% to 12% for the period. Report

> Teva Pharmaceutical ($TEVA) rolled out its version of the injectable thrombin inhibitor Argatroban. Release

Medical Device News

@FierceMedDev: NuVasive gains on $14M DOJ settlement over improper Medicare, Medicaid claims. Story | Follow @FierceMedDev

@VarunSaxena2: Drug testing company Cordant raises $12.8M as it seeks to be fragmented industry's one-stop shop. More | Follow @VarunSaxena2

@EmilyWFierce: #France's Labco looks to make market entree with €545 million IPO. Article | Follow @EmilyWFierce

> Philips ramping up CT scan production following €100M quality improvement plan at Cleveland facility. More

> Kaiser backs startup in $12.5M round to speed healthcare data integration. Story

> NuVasive gains on $14M DOJ settlement over improper Medicare, Medicaid claims. Article

Biotech News

@FierceBiotech: Activists get their way as Ariad CEO Berger steps down. Article | Follow @FierceBiotech

@JohnCFierce: I asked CRISPR Tx CEO Novak if he was prepping an IPO. (Answer: all options open) Felt damn silly even asking, but you have to these days. | Follow @JohnCFierce

@DamianFierce: Zymoquizyme got robbed. RT @CarlyHFierce What's in a (drug) name? We asked the #FierceMadness champs. More | Follow @DamianFierce

> Amgen adding 100 researchers in Cambridge as biotechs scout for 1,000-plus. More

> Celgene bets $30M on a Versant-backed cancer startup. News

> Celgene deepens its Agios ties with an $80M option deal. Story

Biotech Research News

> Mayo Clinic study finds a potential Achilles' heel for HER2-positive cancer. Story

> Better than RNAi? Emory team modifies CRISPR-Cas9 tech for viral infections. News

> Yale collaborators use gene editing tech to fix a cystic fibrosis mutation. Article

> International team opens a 'new frontier' in diabetes research. More

> Google's Calico continues its partnering romp on aging R&D with Buck collaboration. More

Diagnostics News

> Researchers show Adaptive's next-gen sequencing tech can diagnose recurrent Hodgkin lymphoma. Story

> Veracyte unveils $40M private placement to generate cash for R&D. Article

> Biocartis charges ahead with $109M IPO to fuel product development. More

> Drug testing company Cordant raises $12.8M as it seeks to be fragmented industry's one-stop shop. News

> Roche charges ahead with diagnostics R&D after sealing Foundation deal. Report

Pharma Marketing News

> Time for an asthma check, doc? AstraZeneca-sponsored EHR reminders will tell you. More

> GSK buoyed by early numbers on Anoro, Breo DTC campaigns. News

> Merck could be in for big Januvia boost, thanks to 'completely balanced' heart data. Report

> AbbVie says disappointing Viekira sales numbers are misleading. Article

> Pharma earns failing marks for integrity, but it beats advertising. Story

And Finally... Just two weeks of increased high-fructose corn syrup consumption had major--and negative--effects on cholesterol and triglyceride levels, a new study reveals. Report

Suggested Articles

Sixteen years after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.